haku: @indexterm science / yhteensä: 202
viite: 46 / 202
| Tekijä: | Arnst, C. |
| Otsikko: | Blockbuster of bust |
| Lehti: | Business Week
2000 : NOV 13, VOL. 3691:1021, p. 68-70 |
| Asiasana: | SCIENCE BIO-TECHNOLOGY PHARMACEUTICAL INDUSTRY |
| Kieli: | eng |
| Tiivistelmä: | Cell Pathways Inc. CEO Robert J. Towarnicki and Chief Scientific Officer Dr. Rifat Pamukcu were understandibly wary on Oct 3. They were about to go into a meeting with investors at a UBS Warburg life sciences conference just one week after Food & Drug Administration denied approval for the company's lead drug candidate, Aptosyn. The article overviews this situation and presents the history behind the new drug and Cell Pathways Inc. |
SCIMA